Summary The effect of the combined administration of doxorubicin (DX) and verapamil (VRP) on the induction of DX resistance of B16 melanoma cells, was investigated both in vitro and in vivo. Cells grown in the presence of increasing concentrations of DX and of I1M VRP, tested at several passages, were more resistant than cells grown with DX alone. The treatment of B16 melanoma bearing mice with the maximal tolerated dose of DX (12mgkg-1 i.v.) and of VRP (25mgkg-' i.p.) selected a line (B16-DX.VRP) completely resistant to DX after 17 transplants, while treatment with DX alone selected a DX resistant line after 27 transplants. Lung metastases were significantly lower in the B16-DX.VRP line compared to the original B16 melanoma. The results suggest that the association of VRP with DX increases the rate of resistance development to DX.
The calcium channel blocker verapamil (VRP) has been shown to enhance anthracyclines, vincristine and vinblastine cytotoxicity in several resistant cell lines (Tsuruo et al., 1981 (Tsuruo et al., , 1983 Slater et al., 1982; Rogan et al., 1984; Simpson et al., 1984; Pradhan et al., 1984) probably by inhibiting their active efflux (Tsuruo et al., 1981 (Tsuruo et al., ,1982 (Tsuruo et al., ,1983 Rogan et al., 1984) . Recently we have demonstrated that while the coadministration of VRP and doxorubicin (DX) is ineffective in mice bearing tumours against which DX is completely inactive, this combination may result in a significant potentiation of DX activity in mice bearing some sensitive tumours (Formelli et al., 1988) . These in vivo results suggest a potential role of VRP not only after the failure of the secondary treatment, but also in the initial treatment with the aim of eliminating the highest number of tumour cells. Clinical trials combining VRP and DX are in progress both in DX resistant and responsive tumours (Presant et al., 1986; Ozols et al., 1987; Kerr et al., 1986) and the use of VRP with DX from the beginning of tumour treatment poses the question of the effect of this drug on the onset of DX resistance. To answer this question we investigated both in vitro and in vivo the sensitivity to DX of tumour cells exposed during several transplants to DX alone and to DX plus VRP. For this purpose we choose the B16 melanoma, an experimental model which may be representative of a tumour against which the use of DX plus VRP from the beginning can be justified. In fact, it has been shown that, in vivo, B 16 melanoma is a DX sensitive tumour whose sensitivity to DX is significantly increased by coadministration of VRP (Formelli et al., 1988) and in vitro VRP enhances DX cytotoxicity in sensitive and resistant B16 melanoma derived sublines . (Geran et al., 1972) . Tumour bearing mice were divided into two groups. At each transplant, when the tumour was palpable (average tumour diameter= I cm), one group of mice was treated with DX and the other group with DX plus VRP. DX was administered i.v. at the dose of 12mg kg -1, which corresponds to the highest non-lethal dose for this route and schedule in non-tumour bearing mice. VRP was administered i.p. at the dose of 25mg kg-1, which also corresponds to the highest non-lethal dose. VRP was administered according to the schedule previously found effective in increasing DX activity in this tumour (Formelli et al., 1988) . It was administered 3h before DX, since in vitro it potentiates DX activity in pretreated cells . It was administered repeatedly, i.e. 5 days per week, until the tumour was transplanted, since DX levels are maintained in this tumour longer than 7 days (Formelli et al., 1988) . In each group the tumour was transplanted when its weight was 4 times the weight at the time of DX administration. The development of resistance was checked after different passages by comparing DX activity on the parallel transplanted parental B16 line and on the two treated lines designated B16-DX and B16-DX.VRP respectively. The two lines were transplanted in mice not treated with DX for one passage before the anti-tumour activity assays. These assays were performed by transplanting 106 viable (by trypan blue dye exclusion) cells s.c. into B6D2Fl mice (according to Geran et al., 1972) and by treating them with DX i.v. 12mg kg-1, one day after tumour implant. At least 6 animals per group were used. The longest and the shortest tumour diameters were measured by callipers twice a week and tumour weight was estimated according to Geran et al. (1972) . Each animal was checked until death. At autopsy lungs were removed and analysed under a dissecting microscope. The number of metastases per lung were counted, the two diameters of individual metastases were measured and their weight estimated according to Geran et al. (1972) . Statistical analysis of the number and weight of metastases was evaluated by the Mann-Whitney U test (2-tailed). To assess antitumour activity, tumour growth delay (T-C) and median survival times (MST) were also evaluated. T-C is the difference, in number of days, required for the tumours to reach 1g, between treated and control mice. From the evaluation of the significance (Student's t test) of the difference of the tumour weights of treated and control mice 3 weeks after tumour implant a T-C>4 days corresponds to a significant reduction of tumour weight. The significance ofIn vitro studies A B16 melanoma cell line (Bl6V) obtained from the murine B16 melanoma and grown as previously described ) was exposed to continuous increasing concentrations of 10 ng ml -1 DX at almost every passage with or without VRP 1 uM (equivalent to 0.454 jg ml-1). These two cell lines were designated B16V-DX.VRP and B16V-DX respectively. Control cells were maintained in DX-free medium with or without VRP 1 MM. The sensitivity of the 4 cell lines (Bl6V, B16V-VRP, B16V-DX and B16V-DX.VRP) was checked in parallel after different passages from the starting of exposure to DX. A detailed description of the cytotoxicity assay for the evaluation of the resistance index (RI) has been previously reported . Briefly, cells were treated at cell seeding with different concentrations of DX. After 72 h, cells were harvested by trypsinization and counted in a Coulter Counter (ZBI, Electronics, Luton, UK) and cell viability was evaluated by trypan blue dye exclusion. The RI was evaluated as the ratio between the graphically determined concentrations causing a 50% decrease in viable cell number (ID 50) on B16V-DX.VRP and B16V-DX and the ID 50 on B16V cells.
Materials and methods

Drugs
For cell morphology analysis, cells seeded 48 h before were photographed with an inverted Leitz microscope fitted with phase-contrast optic.
Results
In vitro development of drug resistance
The results of the sensitivity assays performed in parallel on B16V-DX and B16V-DX.VRP in 2 separate resistance inductions are reported in Table I . Cells grown in VRP containing medium, B16V-VRP, showed no differences in sensitivity to DX compared to cells grown in drug-free medium (ID 50: 14 ngml-1 vs. lI + 1.9 ngml-1). The increase of DX concentration in the medium of BI6V-DX and B16V-DX.VRP led to an increase in the RI which was higher if cells were grown in the presence of 1 MM VRP. In fact, the cytotoxic effect of similar doses of DX in the two lines was statistically different (P.0.05 Student's t test) in all the assays performed. In the first experiment performed, it was not possible to evaluate DX cytotoxicity in the B16V-DX.VRP line when DX concentration was 100 ng ml-because the line was lost due to cessation of cell replication. In the second experiment, when DX concentration in the medium was lOO ng ml -1, B16V-DX.VRP cells started to slow their replication until no further proliferation was observed and the cell line was lost after few passages. No sign of toxicity was evident in both experiments before cessation of cell Figure 2 , the latter reporting the time course of tumour growth of control and treated mice. In mice bearing B16 melanoma, DX treatment on day 1 caused a significant delay in tumour growth (Figure 2 (Table II) was also observed, even if lower than that (T/C .125%) considered necessary to demonstrate activity (Geran et al., 1972) . If the treatment was given on day 7, there was a significant reduction in the growth of the tumour, but no partial or complete regression ( Figure 2) ; a significant increase in life span was also observed (Table II) . At autopsy, only animals treated on day 1 had a lower number of metastases than the controls (Table II) (Table II) .
After 27 transplants in treated mice, B16-DX also became completely resistant to DX and B16-DX.VRP maintained its resistance ( Figure 2 and Table II B16 controls Mann-Whitney U test.
Discussion
Although the acquisition of tumour drug resistance is presently far from being understood, its development is apparently due to the elimination of drug sensitive cells, leaving preexisting drug resistant cells to predominate. Previous studies on B16 melanoma cells, never exposed to DX before, have shown that VRP, at the doses employed in this study, induces a 1.5-fold increase of DX cytotoxicity in vitro and also a significant increase of DX antitumour effect in vivo (Formelli et al., 1988) . The in vitro studies indicated that the B16V line originally included 20% of DX-resistant cells and the increase of DX cytotoxicity on this line may be due to an effect of VRP on these pre-existing resistant cells, possibly the ones of lower resistance index. In fact it has been shown that VRP can completely reverse DX resistance of human ovarian cancer cells, but only if the degree of resistance is moderate (3-6 fold) while it only partially reverses the resistance of highly (150-fold) resistant cells (Rogan et al., 1984) . Similar considerations apply to previously reported in vivo results (Formelli et al., 1988 (Tsuruo et al., 1983; Rogan et al., 1984) it is possible that this higher cell killing is due to an increase of intracellular DX concentrations and therefore the increased levels of resistance might be due to the fact that cells had been exposed to higher DX concentrations.
It is interesting to note that cells selected by DX plus VRP, besides being more resistant compared to those selected by DX alone, developed features associated with more differentiated cells. In fact, in vitro they showed marked cell-substrate adhesiveness, higher melanin content and a higher number of dendrite-like structures, which are all characteristic markers of normal differentiating melanocytes (Hirobe, 1978) . Similar observations of normalization of cell morphology have been previously reported by DX alone on B 16 melanoma cell lines (Raz, 1982) and on other cell lines made resistant to daunomycin, vincristine and actinomycin D (Biedler et al., 1975) . In vivo the B16-DX.VRP line was slightly less tumorigenic and, as previously reported for B 16VDXR, a B1 6 melanoma line resistant to DX both in vitro and in vivo , it showed a longer and more heterogeneous latency compared to B16. Moreover, similar to the B16VDXR line , the B16-DX.VRP line produced a significantly lower number of metastases compared to the original B 16 tumour. Therefore, the results reported here and previously show that selection by DX both in vitro (B16VDXR line) and in vivo with the addition of VRP (B16-DX.VRP line) leads to cells with diminished metastatic potential. A similar observation of decreased metastases in a B 1 6-BL6 line made resistant to DX both in vitro (B16VDXR line) and in vivo with the
The high degree of cell substrate adhesiveness observed in vitro and the reduced metastatic potential found in vivo suggest that, as reported for other resistant cells, in these cells also, plasma membrane may mediate the expression of drug resistance (Biedler et al. 1975 ; Kartner et al., 1983) . In this regard, it must be pointed out that the effect of VRP as well as that of other agents not affecting calcium levels, but known to circumvent pleiotropic drug resistance, is associated with their interaction with the cell membrane (Ramu et al., 1984; Hindenburg et al., 1987) .
In conclusion, the results of this study suggest that the association of VRP with DX may increase the rate of resistance development to DX. This finding might have potentially important clinical implications particularly for such tumours as small cell lung cancer, a tumour whose sensitivity to DX in association with VRP is currently under test (Kerr et al., 1986) and whose high relapse rate is probably due to acquisition of drug resistance (Smyth et al., 1985) .
